Therefore, in this cancer-derived H-ras mutation a combination of weak biochemical alterations and a significantly increased nanoclustering, which both result in an activating phenotype of the G48R,D92N mutation in H-ras, may explain the occurrence of these two H-ras mutations in the tumor. The gene discussed is HRAS; the disease is cancer.